Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50. https://doi.org/10.1016/j.diabres.2017.03.024.
Article CAS PubMed Google Scholar
Mohebi R, Chen C, Ibrahim NE, McCarthy CP, Gaggin HK, Singer DE, et al. Cardiovascular disease projections in the United States based on the 2020 census estimates. J Am Coll Cardiol. 2022;80(6):565–78.
Article PubMed PubMed Central Google Scholar
Pop-Busui R, Januzzi JL, Bruemmer D, Butalia S, Green JB, Horton WB, et al. Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Diabetes Care. 2022;45(7):1670–90.
Article PubMed PubMed Central Google Scholar
Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27(8):1879–84.
Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure. J Card Fail. 2021;27(4):387–413.
Stanton AM, Vaduganathan M, Chang L-S, Turchin A, Januzzi JL, Aroda VR. Asymptomatic diabetic cardiomyopathy: an underrecognized entity in type 2 diabetes. Curr Diab Rep. 2021;21:1–11.
Karwi QG, Ho KL, Pherwani S, Ketema EB, Sun Q, Lopaschuk GD. Concurrent diabetes and heart failure: interplay and novel therapeutic approaches. Cardiovasc Res. 2022;118(3):686–715. https://doi.org/10.1093/cvr/cvab120.
Article CAS PubMed Google Scholar
Murtaza G, Virk HUH, Khalid M, Lavie CJ, Ventura H, Mukherjee D, et al. Diabetic cardiomyopathy-a comprehensive updated review. Prog Cardiovasc Dis. 2019;62(4):315–26.
Halabi A, Potter E, Yang H, Wright L, Sacre JW, Shaw JE, et al. Association of biomarkers and risk scores with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2022;21(1):278. https://doi.org/10.1186/s12933-022-01711-5.
Article CAS PubMed PubMed Central Google Scholar
From Aaron M, Scott Christopher G, Chen Horng H. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction. J Am Coll Cardiol. 2010;55(4):300–5. https://doi.org/10.1016/j.jacc.2009.12.003.
Article CAS PubMed Google Scholar
Malachias MVB, Jhund PS, Claggett BL, Wijkman MO, Bentley-Lewis R, Chaturvedi N, et al. NT‐proBNP by itself predicts death and cardiovascular events in high‐risk patients with type 2 diabetes mellitus. J Am Heart Assoc. 2020;9(19):e017462. https://doi.org/10.1161/JAHA.120.017462.
Article CAS PubMed PubMed Central Google Scholar
Pandey A, Vaduganathan M, Patel KV, Ayers C, Ballantyne CM, Kosiborod MN, et al. Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes. JACC Heart Fail. 2021;9(3):215–23. https://doi.org/10.1016/j.jchf.2020.10.013.
Article PubMed PubMed Central Google Scholar
Brouwers FP, van Gilst WH, Damman K, van den Berg MP, Gansevoort RT, Bakker SJ, et al. Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort. Circulation: Heart Fail. 2014;7(5):723–31.
Nguyen K, Fan W, Bertoni A, Budoff MJ, Defilippi C, Lombardo D, et al. N-terminal pro B-type natriuretic peptide and high-sensitivity cardiac troponin as markers for heart failure and cardiovascular disease risks according to glucose status (from the multi-ethnic study of atherosclerosis [MESA]). Am J Cardiol. 2020;125(8):1194–201.
Article CAS PubMed Google Scholar
Jia X, Al Rifai M, Ndumele CE, Virani SS, de Lemos JA, Lee E, et al. Reclassification of Pre-heart failure stages using Cardiac biomarkers: the ARIC Study. JACC Heart Fail. 2023;11(4):440–50. https://doi.org/10.1016/j.jchf.2022.12.005. Epub 2023/03/08.
Article PubMed PubMed Central Google Scholar
Januzzi JL Jr, Butler J, Del Prato S, Ezekowitz JA, Ibrahim NE, Lam CS, et al. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart failure trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. Am Heart J. 2023;256:25–36.
Article CAS PubMed Google Scholar
Januzzi James L, Butler J, Del Prato S, Ezekowitz Justin A, Ibrahim Nasrien E, Lam Carolyn SP, et al. Randomized trial of a selective aldose reductase inhibitor in patients with diabetic cardiomyopathy. J Am Coll Cardiol. 2024;84(2):137–48. https://doi.org/10.1016/j.jacc.2024.03.380.
Article CAS PubMed Google Scholar
Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1–64.
Green CP, Porter Charles B, Bresnahan Dennis R, Spertus John A. Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245–55. https://doi.org/10.1016/S0735-1097(00)00531-3.
Article CAS PubMed Google Scholar
Washburn RA, Smith KW, Jette AM, Janney CA. The physical activity scale for the elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46:153–62. https://doi.org/10.1016/0895-4356(93)90053-4.
Article CAS PubMed Google Scholar
Yeung AM, Huang J, Pandey A, Hashim IA, Kerr D, Pop-Busui R, et al. Biomarkers for the diagnosis of heart failure in people with diabetes: a consensus report from diabetes technology society. Prog Cardiovasc Dis. 2023;79:65–79.
Valle R, Bagolin E, Canali C, Giovinazzo P, Barro S, Aspromonte N, et al. The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. Eur J Echocardiography. 2006;7(1):40–4.
Poulsen MK, Dahl JS, Henriksen JE, Hey TM, Høilund-Carlsen PF, Beck-Nielsen H, et al. Left atrial volume index: relation to long-term clinical outcome in type 2 diabetes. J Am Coll Cardiol. 2013;62(25):2416–21. https://doi.org/10.1016/j.jacc.2013.08.1622.
Wang Y, Yang H, Huynh Q, Nolan M, Negishi K, Marwick Thomas H. Diagnosis of nonischemic stage B heart failure in type 2 diabetes mellitus. JACC: Cardiovasc Imaging. 2018;11(10):1390–400. https://doi.org/10.1016/j.jcmg.2018.03.015.
de Gonzalo-Calvo D, Kenneweg F, Bang C, Toro R, van der Meer RW, Rijzewijk LJ, et al. Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes. Sci Rep. 2016;6(1):37354. https://doi.org/10.1038/srep37354.
Article CAS PubMed PubMed Central Google Scholar
Gamella-Pozuelo L, Fuentes-Calvo I, Gómez-Marcos MA, Recio-Rodriguez JI, Agudo-Conde C, Fernández-Martín JL, et al. Plasma Cardiotrophin-1 as a marker of hypertension and diabetes-induced target organ damage and cardiovascular risk. Medicine. 2015;94(30):e1218.
Article CAS PubMed PubMed Central Google Scholar
Shaver A, Nichols A, Thompson E, Mallick A, Payne K, Jones C, et al. Role of serum biomarkers in early detection of diabetic cardiomyopathy in the West Virginian population. Int J Med Sci. 2016;13(3):161–8. https://doi.org/10.7150/ijms.14141.
Article CAS PubMed PubMed Central Google Scholar
Chen WJY, Greulich S, van der Meer RW, Rijzewijk LJ, Lamb HJ, de Roos A, et al. Activin a is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes. Cardiovasc Diabetol. 2013;12(1):150. https://doi.org/10.1186/1475-2840-12-150.
留言 (0)